KEY POINTS
- HypoMast-IMNI (NCT03856372) was a randomized, open-label, phase III noninferiority trial conducted at Fudan University Shanghai Cancer Center. Between September 2018 and July 2022, 1,494 women with high-risk breast cancer were randomized, and 1,429 were included in the modified intention-to-treat analysis (716 hypofractionated RT; 713 conventional RT). Eligible patients had pT1–4N2–3, pT3–4N1, or pT1–2N1 disease with additional high-risk factors; all underwent mastectomy and axillary lymph node dissection with at least 10 nodes removed, while neoadjuvant chemotherapy recipients were excluded.
- Patients received either 42.56 Gy in 16 fractions or 50 Gy in 25 fractions to the chest wall and regional lymphatics, including the undissected axillary, supraclavicular, and internal mammary nodes in the first three intercostal spaces. Approximately 91% of patients were treated using simplified inverse-planned IMRT, with VMAT used in the remainder. Nearly all patients received adjuvant chemotherapy, 21.2% of left-sided patients underwent DIBH, and no chest wall or scar boost was delivered.
- After a median follow-up of 58.1 months, the primary endpoint of five-year locoregional recurrence was 1.7% with hypofractionated RT versus 2.2% with conventional RT, representing an absolute difference of −0.5 percentage points. There were 11 versus 15 locoregional recurrence events, respectively (HR 0.69, 95% CI 0.32–1.51). The shorter regimen met the prespecified noninferiority criterion (p=0.017), with the upper confidence limit remaining below the protocol-defined HR margin of 1.61.
- No significant differences were observed in secondary survival endpoints. Five-year distant metastasis-free survival was 92.3% versus 92.7% (HR 1.00; p=0.987), breast cancer recurrence-free survival 91.8% versus 92.3% (HR 0.99; p=0.980), disease-free survival 88.5% versus 89.4% (HR 1.05; p=0.769), and overall survival 95.1% versus 96.1% (HR 1.21; p=0.476), for hypofractionated and conventional RT, respectively.
- Severe acute skin toxicity was substantially lower with hypofractionation. Grade 3 acute skin reactions occurred in 1.7% versus 12.2% (p<0.001), an absolute reduction of 10.5 percentage points. Grade 1–2 skin pain was also less frequent (7.7% vs 23.3%; p<0.001), as was skin pruritus (26.7% vs 35.2%; p=0.001). Although grade 1–2 skin reactions were more frequent with hypofractionation (95.9% vs 87.7%), the marked reduction in grade 3 events indicates a more favorable severe acute toxicity profile.
- Cardiopulmonary and other late toxicities were comparable between regimens. Grade ≥2 radiation pneumonitis occurred in 2.0% versus 2.1%, and grade ≥2 pulmonary fibrosis in 1.3% in both groups. Clinical lymphedema was reported in 24.0% versus 23.0%, while arm circumference increases exceeding 10% occurred in 7.7% versus 7.3%. No ischemic cardiac events, grade 4 toxicities, or treatment-related deaths were reported, although longer follow-up is required to assess delayed cardiac effects.
- Subgroup analyses showed broadly consistent treatment effects, including in patients with N2–3 disease, for whom five-year locoregional recurrence was 3.0% with hypofractionation versus 4.0% with conventional RT. Nevertheless, the trial recorded only 26 locoregional recurrences, substantially fewer than originally anticipated. Generalizability is also limited by exclusion of neoadjuvant chemotherapy, universal axillary dissection, absence of pT4 and certain N3 subgroups, relatively limited DIBH use, and the small proportion undergoing breast reconstruction (9.3%).
CLINICAL TAKEAWAY
HypoMast-IMNI provides robust randomized evidence supporting 42.56 Gy in 16 fractions as an alternative to 50 Gy in 25 fractions for high-risk breast cancer patients requiring postmastectomy RT with comprehensive regional nodal irradiation, including the internal mammary chain. The shorter schedule achieved noninferior locoregional control and substantially reduced severe acute skin toxicity without increasing observed cardiopulmonary complications, although applicability after neoadjuvant systemic therapy and very long-term cardiac safety require further evaluation.